The C ombined Approach to L ysis Utilizing E ptifibatide a nd r t-PA in Acute Ischemic Stroke | Zendy

Arthur Pancioli | Zendy; Joseph P. Broderick | Zendy; Thomas G. Brott | Zendy; Thomas A. Tomsick | Zendy; Jane Khoury | Zendy; Judy A. Bean | Zendy; Gregory del Zoppo | Zendy; Dawn Kleindorfer | Zendy; Daniel Woo | Zendy; Pooja Khatri | Zendy; John Castaldo | Zendy; James L. Frey | Zendy; James Gebel | Zendy; Scott E. Kasner | Zendy; Chelsea S. Kidwell | Zendy; Thomas Kwiatkowski | Zendy; Richard Libman | Zendy; Richard S. Mackenzie | Zendy; Phillip Scott | Zendy; Sidney Starkman | Zendy; R. Jason Thurman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The C ombined Approach to L ysis Utilizing E ptifibatide a nd r t-PA in Acute Ischemic Stroke

Author(s) -

Arthur Pancioli,

Joseph P. Broderick,

Thomas G. Brott,

Thomas A. Tomsick,

Jane Khoury,

Judy A. Bean,

Gregory del Zoppo,

Dawn Kleindorfer,

Daniel Woo,

Pooja Khatri,

John Castaldo,

James L. Frey,

James Gebel,

Scott E. Kasner,

Chelsea S. Kidwell,

Thomas Kwiatkowski,

Richard Libman,

Richard S. Mackenzie,

Phillip Scott,

Sidney Starkman,

R. Jason Thurman

Publication year - 2008

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.108.517656

Subject(s) - medicine , eptifibatide , thrombolysis , stroke (engine) , clinical endpoint , randomized controlled trial , myocardial infarction , bolus (digestion) , fibrinolytic agent , tissue plasminogen activator , anesthesia , surgery , percutaneous coronary intervention , mechanical engineering , engineering

Multiple approaches are being studied to enhance the rate of thrombolysis for acute ischemic stroke. Treatment of myocardial infarction with a combination of a reduced-dose fibrinolytic agent and a glycoprotein (GP) IIb/IIIa receptor antagonist has been shown to improve the rate of recanalization versus fibrinolysis alone. The combined approach to lysis utilizing eptifibatide and recombinant tissue-type plasminogen activator (rt-PA) (CLEAR) stroke trial assessed the safety of treating acute ischemic stroke patients within 3 hours of symptom onset with this combination.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research